A farnesyltransferase inhibitor attenuated beta-adrenergic receptor downregulation in rat skeletal muscle.
Farnesylation represents an essential posttranslational modification of several well-defined proteins implicated in the homologous desensitization of the beta-adrenergic receptor (beta-ADR). The following study examined the effect of a novel farnesyltransferase inhibitor, BMS-191563, on agonist-mediated beta-ADR downregulation in skeletal muscle. Female Sprague-Dawley rats were treated for 12 days with the beta2-adrenergic agonist clenbuterol (4 mg/kg) with or without the concurrent administration of BMS-191563 (2 mg x kg(-1) x day(-1)). Clenbuterol promoted gastrocnemius muscle hypertrophy, whereas the soleus muscle was unaffected. Total beta-ADR density was decreased by 45 and 40% in the soleus and medial gastrocnemius (MG), respectively, after clenbuterol treatment. BMS-191563 treatment did not prevent clenbuterol-stimulated MG hypertrophy, but markedly attenuated beta-ADR downregulation in both muscle types. This latter effect in the soleus muscle was not associated with the inhibition of Ras farnesylation. Likewise, in rat cardiac fibroblasts, isoproterenol-mediated decrease of total beta-ADR density was abrogated by the prior treatment with BMS-191563. Collectively, these data demonstrate that the mechanism(s) implicated in agonist-mediated beta-ADR downregulation was sensitive to BMS-191563, thereby suggesting the involvement of farnesylated proteins.